Octreo Ratiopharm (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreo Ratiopharm, is a somatostatin analog presented as a sterile solution for intramuscular and intravenous use. It is employed to control hormone‑related disorders such as acromegaly, carcinoid syndrome diarrhea, VIPoma diarrhea, postoperative pancreatic fistula, and esophageal variceal bleeding.

GNH USA supplies Octreo Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Octreo Ratiopharm acts on somatostatin receptors to modulate hormone secretion in several endocrine and gastrointestinal conditions. - Acromegaly: reduces excess growth hormone secretion, helping control disease activity. - Carcinoid syndrome diarrhea: decreases serotonin‑mediated intestinal secretions, alleviating watery stools. - VIPoma diarrhea: suppresses vasoactive intestinal peptide release, reducing severe diarrhoea. - Postoperative pancreatic fistula: lowers pancreatic exocrine output, aiding fistula closure. - Esophageal variceal bleeding: diminishes portal pressure by inhibiting gastrointestinal hormones, supporting haemostasis.

Octreo Ratiopharm may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal pain: cramping or discomfort. - Diarrhoea: increased loose stools. - Injection site reactions: redness, swelling, or pain. - Hyperglycaemia: elevated blood glucose levels. - Gallstone formation: biliary sludge or stones.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypoglycaemia: dangerously low blood sugar, especially in diabetic patients. - Cardiac arrhythmia: irregular heart rhythm, may require monitoring. - Anaphylaxis: acute allergic reaction with airway compromise.

When using Octreo Ratiopharm, clinicians should observe several safety measures. - Monitor glucose levels: octreotide can alter blood sugar, requiring regular checks. - Assess gallbladder status: prolonged therapy may promote gallstone development. - Evaluate cardiac function: watch for bradycardia or arrhythmias. - Use cautiously in renal or hepatic impairment: adjust monitoring as needed. - Review concomitant hormone therapies: interactions may affect efficacy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreo Ratiopharm can interact with other medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Octreotide + insulin: may mask hypoglycaemia symptoms; avoid abrupt insulin changes. - Octreotide + other somatostatin analogs: additive hormonal suppression can lead to severe endocrine effects.

Moderate Interactions (Monitor Closely): - Octreotide + quinidine: monitor QT interval for prolongation. - Octreotide + cyclosporine: observe renal function and drug levels. - Octreotide + oral contraceptives: reduced contraceptive efficacy; consider alternative methods.